Literature DB >> 3017935

Bovine brain-derived growth factor. Purification and characterization of its interaction with responsive cells.

J S Huang, S S Huang, M D Kuo.   

Abstract

A large-scale purification procedure for brain-derived growth factors, without chromatography in 0.1% trifluoracetic acid, has been developed. Two related brain-derived growth factors have been purified to homogeneity from bovine brain using this procedure involving ammonium sulfate fractionation, followed by chromatography on CM-Sephadex C-50, sulfated Sephadex G-50, and heparin-Sepharose 4B. Brain-derived growth factor A (BDGF-A, molecular weight approximately 16,000) and brain-derived growth factor B (BDGF-B, molecular weight approximately 17,000) were eluted from heparin-Sepharose 4B at 1.2 and 1.6 M NaCl, respectively. Both BDGF-A and BDGF-B have a pI value of 5.7, have the same specific mitogenic activity, and react with mouse anti-BDGF-A antiserum. Both growth factors have a broad spectrum of mitogenic activity (vascular and aorta endothelial cells, chondrocytes, osteoblasts, epithelial cells, glial cells, fibroblasts, and smooth muscle cells), with a half-maximum effect at 10-20 pM. The binding of BDGF to bovine aorta endothelial cells and Swiss mouse 3T3 cells has been characterized. Binding of 125I-BDGF-A to these cells reached equilibrium in less than 15 min. Scatchard plot analysis of the binding of 125I-BDGF-A to endothelial cells and 3T3 cells showed a single class of high-affinity receptor with Kd values of 20 +/- 5 and 13 +/- 3 pM and receptor numbers/cell of 7,000 +/- 1,000 and 20,000 +/- 3,000, respectively. BDGF-B competed for 125I-BDGF-A binding in the same manner as unlabeled BDGF-A, suggesting that BDGF-A and BDGF-B bind to the same receptor. Basic pituitary fibroblast growth factor appeared to be a weak inhibitor, whereas platelet-derived growth factor and epidermal growth factor had no effect on 125I-BDGF-A binding. Protamine, histone, polylysine, and polyarginine are potent inhibitors of the mitogenic activity of BDGF-A and BDGF-B and of binding of 125I-BDGF-A to responsive cells. The half-time (t1/2) of internalization and degradation of cell surface-bound 125I-BDGF is 3 h.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 3017935

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  13 in total

1.  Heparin-binding growth factors and their receptors.

Authors:  B B Olwin
Journal:  Cytotechnology       Date:  1989-12       Impact factor: 2.058

Review 2.  Fibroblast (heparin-binding) growing factors in neuronal development and repair.

Authors:  L W Haynes
Journal:  Mol Neurobiol       Date:  1988       Impact factor: 5.590

Review 3.  Antiangiogenesis as a novel therapeutic concept in pediatric oncology.

Authors:  L Schweigerer
Journal:  J Mol Med (Berl)       Date:  1995-10       Impact factor: 4.599

Review 4.  Suramin: an anticancer drug with unique biological effects.

Authors:  A K Larsen
Journal:  Cancer Chemother Pharmacol       Date:  1993       Impact factor: 3.333

5.  Heparin-binding growth factor 1 stimulates tyrosine phosphorylation in NIH 3T3 cells.

Authors:  R Friesel; W H Burgess; T Maciag
Journal:  Mol Cell Biol       Date:  1989-05       Impact factor: 4.272

6.  Three-dimensional structure of human basic fibroblast growth factor.

Authors:  A E Eriksson; L S Cousens; L H Weaver; B W Matthews
Journal:  Proc Natl Acad Sci U S A       Date:  1991-04-15       Impact factor: 11.205

7.  Mr 25,000 heparin-binding protein from guinea pig brain is a high molecular weight form of basic fibroblast growth factor.

Authors:  D Moscatelli; J Joseph-Silverstein; R Manejias; D B Rifkin
Journal:  Proc Natl Acad Sci U S A       Date:  1987-08       Impact factor: 11.205

8.  Suramin interferes with interleukin-6 receptor binding in vitro and inhibits colon-26-mediated experimental cancer cachexia in vivo.

Authors:  G Strassmann; M Fong; C E Freter; S Windsor; F D'Alessandro; R P Nordan
Journal:  J Clin Invest       Date:  1993-11       Impact factor: 14.808

9.  Astroglial growth factors in normal human brain and brain tumors: comparison with embryonic brain.

Authors:  M P Rathbone; G K Szlapetis; R de Villiers; R F Del Maestro; J Gilbert; J Groves; K Erola; J K Kim
Journal:  J Neurooncol       Date:  1992-03       Impact factor: 4.130

10.  Suramin is an inhibitor of DNA topoisomerase II in vitro and in Chinese hamster fibrosarcoma cells.

Authors:  K Bojanowski; S Lelievre; J Markovits; J Couprie; A Jacquemin-Sablon; A K Larsen
Journal:  Proc Natl Acad Sci U S A       Date:  1992-04-01       Impact factor: 11.205

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.